Table 1 Baseline characteristics of CAD patient population. Significant values (p < 0.05) are highlighted.
All | No adverse events | Adverse events | p-value | |
|---|---|---|---|---|
(n = 595) | (n = 554; 93.1%) | (n = 41; 6.9%) | ||
Female, n (%) | 174 (29.2) | 166 (30) | 8 (19.5) | 0.156 |
Age, years (mean ± SD) | 70 (± 11.4) | 69.7 (± 11.4) | 74 (± 11.4) | 0.026 |
Body mass index (mean ± SD) | 27.4 (± 5.1) | 27.5 (± 5.1) | 26.8 (± 4.3) | 0.308 |
Cardiovascular risk factors | ||||
Arterial hypertension, n (%) | 532 (89.4) | 496 (89.5) | 36 (87.8) | 0.729 |
Hyperlipidemia, n (%) | 473 (79.5) | 440 (79.4) | 33 80.5) | 0.871 |
Diabetes mellitus, n (%) | 193 (32.4) | 178 (32.1) | 15 (36.6) | 0.557 |
HbA1c (%) (mean ± SD) | 6.3 (± 1.1) | 6.3 (± 1.1) | 6.4 (± 1.2) | 0.736 |
Current smoking, n (%) | 113 (19.1) | 108 (19.6) | 5 (12.2) | 0.246 |
Ex Smoking > 6 mo, n (%) | 129 (21.8) | 119 (21.6) | 10 (24.4) | 0.672 |
Obesity, n (%) | 139 (23.4) | 129 (23.3) | 10 (24.4) | 0.671 |
Atrial Fibrillation, n (%) | 139 (23.4) | 126 (22.8) | 13 (31.7) | 0.195 |
Previous CABG, n (%) | 22 (3.7) | 19 (3.4) | 3 (7.3) | 0.203 |
Previous MI, n (%) | 131 (22) | 123 (22.2) | 8 (19.5) | 0.688 |
Renal function (GFR) (mean ± SD) | 80.2 (± 28.8) | 80.4 (± 28.8) | 78.1 (± 29.8) | 0.638 |
Medication on admission | ||||
Statins, n (%) | 497 (83.5) | 462 (83.4) | 35 (85.4) | 0.743 |
Ezetimibe, n (%) | 83 (13.9) | 79 (14.3) | 4 (9.8) | 0.420 |
Acetylsalicylic acid, n (%) | 543 (91.3) | 508 (91.7) | 35 (85.4) | 0.166 |
Clopidogrel, n (%) | 264 (44.4) | 249 (45) | 15 (36.6) | 0.299 |
Ticagrelor, n (%) | 133 (22.4) | 124 (22.4) | 9 (22) | 0.944 |
Prasugrel, n (%) | 112 (18.9) | 107 (19.4) | 5 (12.2) | 0.259 |
Cangrelor, n (%) | 1 (0.2) | 1 (0.2) | 0 (0) | 0.785 |
Oral anticoagulants, n (%) | 130 (21.9) | 116 (20.9) | 14 (34.2) | 0.060 |
Angiotensin-converting enzyme inhibitors, n (%) | 194 (32.6) | 182 (32.9) | 12 (29.3) | 0.637 |
Angiotensin II receptor antagonists, n (%) | 312 (52.4) | 292 (52.7) | 20 (48.8) | 0.627 |
Aldosterone antagonists, n (%) | 152 (25.6) | 142 (25.6) | 10 (24.4) | 0.860 |
Ca channel antagonists, n (%) | 211 (35.5) | 196 (35.4) | 15 (36.6) | 0.876 |
β-blockers, n (%) | 418 (70.3) | 386 (69.9) | 32 (78.1) | 0.258 |
Diuretics, n (%) | 209 (35.2) | 194 (35.1) | 15 (36.6) | 0.846 |
Lipid profile parameters | ||||
LDL-cholesterol (mg/dL) (mean ± SD) | 107.5 (± 43.8) | 107.5 (± 43.5) | 107.4 (± 47.2) | 0.988 |
HDL-cholesterol (mg/dL) (mean ± SD) | 45.5 (± 16.2) | 45.4 (± 16.3) | 46.5 (± 16.2) | 0.689 |
Triglycerides (mg/dL) (mean ± SD) | 141.1 (± 87.2) | 142.6 (± 88.3) | 120.3 (± 68.7) | 0.055 |
Total cholesterol (mg/mL) (mean ± SD) | 165.8 (± .45.4) | 165.8 (± 44.8) | 164. (± 52.7) | 0.908 |
Platelets (mean ± SD) | 227.6 (± 65.9) | 228.5 (± 65.6) | 215.9 (± 68.4) | 0.261 |
Disease | ||||
Chronic coronary syndrome, n (%) | 227 (38.2) | 210 (37.9) | 17 (41.5) | 0.651 |
Unstable Angina, n (%) | 87 (14.6) | 85 (15.3) | 2 (4.9) | 0.067 |
NSTEMI, n (%) | 210 (35.3) | 191 (34.5) | 19 (46.3) | 0.125 |
STEMI, n (%) | 71 (11.9) | 68 (12.3) | 3 (7.3) | 0.345 |
